Suresh S. Ramalingam, MD, FACP, FASCO



Nationally recognized for his research, Dr. Ramalingam has developed individualized therapies for patients with small cell and non-small cell lung cancer.

Titles and Roles

Professor, Department of Hematology and Medical Oncology
Emory University School of Medicine
Roberto C. Goizueta Distinguished Chair for Cancer Research
Emory University School of Medicine
Executive Director
Winship Cancer Institute of Emory University
Associate Vice President for Cancer
Woodruff Health Sciences Center
Medical Oncologist
Lung Cancer
Research Program
Discovery and Developmental Therapeutics


Board certified in medical oncology, Suresh S. Ramalingam, MD, FACP, FASCO, is nationally recognized as an investigator and a physician in the area of small cell and non-small cell lung cancer.

Dr. Ramalingam serves as executive director of Winship Cancer Institute of Emory University and associate vice president for cancer of Woodruff Health Sciences Center. He is past-president of the Georgia Society of Oncology and a member of the board of Georgia CORE. He is a Fellow of the American Society of Clinical Oncology and a Georgia Cancer Coalition Distinguished Cancer Scholar.

Dr. Ramalingam holds professional memberships with American Society of Clinical Oncology, American Association for Cancer Research, and International Association of Lung Cancer Study. He plays an active role in the ECOG-ACRIN Cancer Research Group as the Chair of the Thoracic Malignancies Committee and as the Deputy Chair of Therapeutics Programs. He serves on several international, national and institutional committees. He is a member of the Medical Oncology Board Exam Committee for American Board of Internal Medicine.


Dr. Ramalingam is a graduate of Kilpauk Medical College at the University of Madras in Madras, India. He completed his residency in internal medicine at Wayne State University in Detroit, Michigan, and his fellowship in hematology and medical oncology at the University of Pittsburgh Cancer Institute in Pittsburgh, Pennsylvania.


Dr. Ramalingam's present research involves developing immune checkpoint inhibitors and improving outcomes for patients with EGFR mutation. He has conducted several phase 1, 2 and 3 clinical trials with molecularly targeted agents in the treatment of small cell and non-small cell lung cancer.

  • Below is a listing of current federal grants for the above principal investigator.



Dr. Ramalingam has authored over 300 scientific publications. He serves as editor-in-chief of CANCER, a peer-reviewed journal of the American Cancer Society.

  • PublicationsPublication Date


As a physician scientist, Dr. Ramalingam has received numerous peer-reviewed grants from the National Cancer Institute. He is also the recipient of several awards including the James Eckman Award for Excellence in Teaching at Emory, ECOG-ACRIN Young Investigator Award, and NCI Cancer Clinical Investigator Team Leadership Award. He has been consistently listed in Atlanta Magazine's annual "Top Doctors" issue since 2018.

Dr. Ramalingam has been named to the MilliPub Club, which recognizes current Emory University School of Medicine faculty who have published one or more individual papers throughout their careers that have garnered more than 1,000 citations.

Additional Websites

Cascade Link   TOP